Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LOMOTIL vs DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: June 2026 · OpiCalc Medical Review Team
Diphenoxylate is a meperidine congener that acts as an opioid receptor agonist, inhibiting gastrointestinal motility and prolonging transit time; atropine is added to discourage abuse at high doses.
Diphenoxylate is a synthetic opioid agonist that acts on mu-opioid receptors in the gastrointestinal tract to reduce peristalsis and prolong transit time. Atropine is added in subtherapeutic doses to discourage intentional overdose and provides anticholinergic effects.
Adjunctive therapy for diarrhea,Symptomatic control of acute nonspecific diarrhea,Chronic diarrhea associated with inflammatory bowel disease
Adjunctive therapy for diarrhea,Management of acute nonspecific diarrhea,Treatment of chronic diarrhea associated with inflammatory bowel disease
Adults: 2 tablets (2.5 mg diphenoxylate/0.025 mg atropine) orally four times daily until control of diarrhea is achieved; maintenance dose is 2 tablets once or twice daily. Maximum dose: 8 tablets (20 mg diphenoxylate) per day.
Each tablet contains diphenoxylate HCl 2.5 mg and atropine sulfate 0.025 mg. Adults: 2 tablets orally 4 times daily until diarrhea controlled, then reduce dose. Maximum 8 tablets per day for 2 days.
Diphenoxylate: 2.5-3.5 hours; Difenoxin (active metabolite): 12-24 hours. Clinically, antidiarrheal effect is prolonged due to metabolite accumulation.
Diphenoxylate: 2.5-12 hours (parent drug); difenoxin (active metabolite): 12-14 hours. Atropine: 2-4 hours. Clinical context: extended half-life of difenoxin allows twice-daily dosing for antidiarrheal effect.
Not studied. Use with caution due to potential accumulation of active metabolites. No specific GFR-based dosing recommendations; avoid in severe renal impairment.
Avoid use in severe renal impairment (GFR < 30 m L/min); no specific dose adjustment guidelines available for mild-moderate impairment, use with caution.
Risk of respiratory depression, especially in children; not recommended in children younger than 6 years. Concomitant use with alcohol or CNS depressants may increase risk.
First trimester: Limited data; diphenoxylate and atropine are not associated with major malformations in animal studies, but human data are insufficient. Second and third trimesters: No evidence of fetal harm, but prolonged use may cause neonatal withdrawal or anticholinergic effects. Use only if benefit outweighs risk.
FDA Pregnancy Category C. First trimester: Limited human data; animal studies show fetal toxicity at high doses. Second/third trimesters: Use only if benefit outweighs risk; may cause neonatal withdrawal if maternal dependence. Avoid prolonged use near term; atropine may cause neonatal anticholinergic effects.
Lomotil (diphenoxylate/atropine) is an antidiarrheal with opioid agonist activity; use cautiously in patients with inflammatory bowel disease due to risk of toxic megacolon. Avoid in children under 6 years. Monitor for CNS depression, especially in combination with other CNS depressants. Atropine component may cause anticholinergic effects (dry mouth, blurred vision, urinary retention). Onset is rapid, but avoid exceeding recommended doses; may cause physical dependence with prolonged use.
Diphenoxylate/atropine is a schedule V controlled substance due to diphenoxylate's opioid activity. Atropine is added at subtherapeutic doses to discourage abuse. Onset of action is 45-60 minutes; duration is 3-4 hours. Avoid in children <6 years due to risk of respiratory depression and atropine toxicity. Do not exceed recommended doses; high doses can cause opioid euphoria. Use with caution in patients with inflammatory bowel disease as it may precipitate toxic megacolon. Monitor for CNS depression, especially with concurrent CNS depressants. Discontinue if no response within 48 hours.
No interactions on record
No interactions on record
Common clinical questions about LOMOTIL vs DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, answered by our medical review team.
LOMOTIL is a Antidiarrheal that works by Diphenoxylate is a meperidine congener that acts as an opioid receptor agonist, inhibiting gastrointestinal motility and prolonging transit time; atropine is added to discourage abuse at high doses.. DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE is a Antidiarrheal that works by Diphenoxylate is a synthetic opioid agonist that acts on mu-opioid receptors in the gastrointestinal tract to reduce peristalsis and prolong transit time. Atropine is added in subtherapeutic doses to discourage intentional overdose and provides anticholinergic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LOMOTIL and DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE depend on the specific clinical indication. These are both Antidiarrheal agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LOMOTIL is: Adults: 2 tablets (2.5 mg diphenoxylate/0.025 mg atropine) orally four times daily until control of diarrhea is achieved; maintenance dose is 2 tablets once or twice daily. Maximum dose: 8 tablets (20 mg diphenoxylate) per day.. The standard adult dose of DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE is: Each tablet contains diphenoxylate HCl 2.5 mg and atropine sulfate 0.025 mg. Adults: 2 tablets orally 4 times daily until diarrhea controlled, then reduce dose. Maximum 8 tablets per day for 2 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LOMOTIL and DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LOMOTIL is classified as Category C. First trimester: Limited data; diphenoxylate and atropine are not associated with major malformations in animal studies, but human data are insufficient. Second and third trimester. DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE is classified as Category C. FDA Pregnancy Category C. First trimester: Limited human data; animal studies show fetal toxicity at high doses. Second/third trimesters: Use only if benefit outweighs risk; may ca. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.
Diphenoxylate is metabolized primarily by the liver to diphenoxylic acid (active metabolite); CYP enzymes involved (mainly CYP3A4).
Diphenoxylate: primarily hepatic metabolism via ester hydrolysis to diphenoxylic acid (active metabolite); also metabolized by CYP3A4. Atropine: hepatic metabolism via glucuronidation and oxidative metabolism.
Primarily renal (50-70% as metabolites, <5% unchanged) and fecal (30-50% via biliary excretion).
Diphenoxylate is primarily excreted in feces via biliary elimination (approx. 50%) and renal excretion (approx. 50% as metabolites); atropine is mainly excreted renally (30-50% unchanged and metabolites).
90% (diphenoxylate) and 80% (difenoxin) bound primarily to albumin.
Diphenoxylate: >90% bound to plasma proteins (albumin). Atropine: 44% bound to albumin.
Diphenoxylate: 3.0-5.0 L/kg; difenoxin: 2.5-4.0 L/kg. Indicates extensive tissue distribution.
Diphenoxylate: Vd approximately 5-10 L/kg (extensive tissue distribution). Atropine: Vd 1-2 L/kg.
Oral: approximately 90% (first-pass metabolism to difenoxin).
Oral: diphenoxylate bioavailability ~90%; atropine bioavailability ~30-50% due to first-pass metabolism.
Child-Pugh A: No adjustment; dose cautiously. Child-Pugh B: Reduce dose by 50% or avoid. Child-Pugh C: Do not use.
Contraindicated in severe hepatic impairment (Child-Pugh class C); in moderate impairment (Child-Pugh class B) use with caution, reduce initial dose by 50% and monitor closely.
Children 2-12 years: Use oral solution (0.25 mg diphenoxylate/m L). Dose: 0.3-0.4 mg/kg of diphenoxylate orally per day in 4 divided doses. Maximum: 4 m L (1 mg diphenoxylate) per dose for 2-5 years; 6 m L (1.5 mg) per dose for 5-8 years; 8 m L (2 mg) per dose for 8-12 years. Not recommended for children <2 years.
Not recommended in children < 2 years; age 2-5: 0.3-0.4 mg/kg/day diphenoxylate divided into 4 doses (max 2 mg/day); age 5-12: 2.5-5 mg diphenoxylate 3-4 times daily.
Initiate at lower doses (e.g., 2 tablets once daily) due to increased sensitivity to anticholinergic effects (atropine), risk of dehydration, and potential for central nervous system toxicity. Titrate cautiously; avoid prolonged use.
Use with caution due to increased sensitivity to anticholinergic effects; initiate at lower doses (e.g., 1 tablet 2-3 times daily) and titrate slowly.
Concomitant use with opioids for cough control or tramadol may increase risk of respiratory depression, particularly in children. Not approved for pediatric use under 6 years of age due to risk of respiratory depression.
May cause respiratory depression in overdose, especially in children; monitor for signs of anticholinergic effects; use with caution in patients with hepatic disease, renal impairment, dehydration, electrolyte imbalances, or history of opioid dependence; discontinue if constipation or abdominal distension occurs; may exacerbate diarrhea secondary to antibiotic-associated colitis or toxic megacolon.
Hypersensitivity to diphenoxylate or atropine; pediatric patients <6 years of age; obstructive jaundice; severe hepatic impairment; diarrhea associated with pseudomembranous colitis or enterotoxin-producing bacteria; concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuation
No specific food interactions reported. However, avoid grapefruit juice as it may theoretically affect metabolism via CYP3A4 inhibition (diphenoxylate is metabolized by CYP3A4). Maintain adequate fluid intake to prevent dehydration. Avoid alcohol during therapy.
Avoid alcohol and grapefruit juice. Alcohol potentiates CNS depression. Grapefruit juice may alter metabolism. No other significant food interactions.
Atropine is excreted in breast milk in small amounts; diphenoxylate presence is unknown. M/P ratio not established. Potential for anticholinergic effects in infant, including gastrointestinal disturbances. Avoid use during breastfeeding unless essential.
Excreted in breast milk in low amounts; atropine may suppress lactation. M/P ratio not established. Avoid breastfeeding due to potential for infant anticholinergic effects and respiratory depression.
Dose adjustment not typically required; pharmacokinetic changes in pregnancy (e.g., increased volume of distribution) are not clinically significant for this drug. Use lowest effective dose for shortest duration.
No standard dose adjustment recommended. Pharmacokinetic changes in pregnancy may increase clearance; however, due to risk of toxicity, use lowest effective dose for shortest duration. Individualize based on response and tolerance.
Take exactly as prescribed; do not exceed the recommended dose.,Do not use for more than 2 days unless directed by a doctor.,Avoid alcohol and other CNS depressants (e.g., sedatives, tranquilizers) as they may increase drowsiness and dizziness.,Drink plenty of clear fluids to prevent dehydration caused by diarrhea.,Contact your healthcare provider if diarrhea persists for more than 2 days or if you develop a fever or blood in stool.,This medication may cause dry mouth, blurred vision, or constipation; report any severe or persistent symptoms.,Keep out of reach of children; accidental overdose can cause severe respiratory depression.,Do not use if you have a history of glaucoma, enlarged prostate, or liver disease without consulting your doctor.
Take exactly as prescribed; do not exceed the recommended dose or duration.,This medication may cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how it affects you.,Avoid alcohol and other central nervous system depressants (e.g., sedatives, tranquilizers) as they may increase drowsiness and risk of serious side effects.,Do not use for more than 2 days unless directed by your doctor; prolonged use can lead to dependence and opioid addiction.,If you have a fever or bloody diarrhea, stop taking this medication and contact your healthcare provider immediately.,Keep out of reach of children; accidental overdose can be fatal due to respiratory depression.,Store at room temperature away from moisture and heat.